Cancer clinical trials in the region Bourgogne-Franche-Comté

218 currently recruiting clinical trials
Region Bourgogne-Franche-Comté
Phase 3 Stomach and esophageal cancer #NCT06731478 #2024-513122-27-00
Required histologic types
Stomach Oesogastric junction
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
15 recruiting sites
Daiichi Sankyo
Phase 3 Breast cancer #NCT07106632 #2024-519655-28-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery
25 recruiting sites
UNICANCER
Phase 3 Skin cancer #NCT06112314
Required histologic types
Melanoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
12 recruiting sites
Immunocore Ltée
Phase 3 Colon cancer Rectal cancer #NCT06642844
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Centre Hospitalier Universitaire de Tours
Phase 3 Breast cancer #NCT05696626 #2023-503708-10-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ESR
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Targeted therapy Hormone therapy
Excluded genetic anomalies
Other mutation
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
Sermonix Pharmaceuticals Inc.
Phase 3 Colon cancer Rectal cancer #NCT07222800 #2025-523521-18-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
BRAF MSI/dMMR
7 recruiting sites
Pfizer
Phase 3 Brain tumors / Central nervous system tumors #NCT05476939 #2014-001929-32
Required histologic types
Gliomas
Required histologic sub types
Diffuse midline glioma grade IV
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Chemotherapy Radiotherapy
33 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3 Brain tumors / Central nervous system tumors #NCT05476939 #2014-001929-32
Phase inclusion - gliomes diffus de la ligne médiane non-DIPG
Required histologic types
Gliomas
Required histologic sub types
Diffuse midline glioma grade IV
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Chemotherapy Radiotherapy
34 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3 Lymphoma #NCT06006117 #2022-501810-77-00
Required histologic types
B cell lymphoma
Required histologic sub types
Marginal zone lymphoma
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min 50-60 ml/min 30-50 ml/min
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Chemotherapy Targeted therapy Monoclonal antibodies
Excluded previous treatments
Systemic Treatment-Naive Bispecific T-cell engager antibodies Allogeneic stem cell transplant
23 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)
Phase 3 Endometrial cancer #NCT07166094
Required histologic sub types
Endometrioid adenocarcinoma Serous adenocarcinoma Clear cell carcinoma Dedifferentiated and undifferentiated endometrial ... Other
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
Genmab